Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 458

The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.

Effect of Evolocumab on Coronary Plaque Phenotype and Burden in Statin-Treated Patients Following Myocardial Infarction

Open access
Nicholls, Stephen J., Kataoka, Yu, Nissen, Steven E., Prati, Francesco, Windecker, Stephan, Puri, Rishi, Hucko, Thomas, Aradi, Daniel, Herrman, Jean-Paul R., Hermanides, Renicus S., Wang, Bei, Wang, Huei, Butters, Julie, Di Giovanni, Giuseppe, Jones, Stephen, Pompili, Gianluca, Psaltis, Peter J.·2022·JACC: Cardiovascular Imaging

Abstract

OBJECTIVES The purpose of this study was to determine the effect of evolocumab on optical coherence tomography (OCT) measures of plaque composition. BACKGROUND The proprotein convertase subtilisin kexin type-9 inhibitor evolocumab produced coronary atheroma regression in statin-treated patients. METHODS Patients with a non-ST-segment elevation myocardial infarction were treated with monthly evolocumab 420 mg (n = 80) or placebo (n = 81) for 52 weeks. Patients underwent serial OCT and intravascular ultrasound imaging within a matched arterial segment of a nonculprit vessel. The primary analysis determined the change in the minimum fibrous cap thickness and maximum lipid arc throughout the imaged arterial segment. Additional analyses determined changes in OCT features in lipid-rich plaque regions and plaque burden. Safety and tolerability were evaluated. RESULTS Among treated patients, (age 60.5 ± 9.6 years; 28.6% women; low-density lipoprotein cholesterol [LDL-C], 141.3 ± 33.1 mg/dL), 135 had evaluable imaging at follow-up. The evolocumab group achieved lower LDL-C levels (28.1 vs 87.2 mg/dL; P < 0.001). The evolocumab group demonstrated a greater increase in minimum fibrous cap thickness (+42.7 vs +21.5 μm; P = 0.015) and decrease in maximum lipid arc (-57.5o vs. -31.4o; P = 0.04) and macrophage index (-3.17 vs -1.45 mm; P = 0.04) throughout the arterial segment. Similar benefits of evolocumab were observed in lipid-rich plaque regions. Greater regression of percent atheroma volume was observed with evolocumab compared with placebo (-2.29% ± 0.47% vs -0.61% ± 0.46%; P = 0.009). The groups did not differ regarding changes in microchannels or calcium. CONCLUSIONS The combination of statin and evolocumab after a non-ST-segment elevation myocardial infarction produces favorable changes in coronary atherosclerosis consistent with stabilization and regression. This demonstrates a potential mechanism for the improved clinical outcomes observed achieving very low LDL-C levels following an acute coronary syndrome. (Imaging of Coronary Plaques in Participants Treated With Evolocumab; NCT03570697).

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.jcmg.2022.03.002

Cites

29 of 29 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 29 references

Cited by

See all 458

Metadata

Authors
Nicholls, S. J., Kataoka, Y., Nissen, S. E., Prati, F., Windecker, S., Puri, R., Hucko, T., Aradi, D., Herrman, J.-P. R., Hermanides, R. S., Wang, B., Wang, H., Butters, J., Di Giovanni, G., Jones, S., Pompili, G., & Psaltis, P. J.
Venue
JACC: Cardiovascular Imaging
Publisher
Elsevier BV
Published
2022-07
Volume
15
Issue
7
Pages
1308-1321
ISSN
  • 1876-7591 (ISSN-L)
  • 1936-878X
OpenAlex
W4220854669
Cited by
458
References
29
FWCI
76.51
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Effect of Evolocumab on Coronary Plaque Phenotype and Burden in Statin-Treated Patients Following Myocardial Infarction. https://app.cochat.ai/papers/10.1016/j.jcmg.2022.03.002
The paper
Nicholls, S. J., Kataoka, Y., Nissen, S. E., Prati, F., Windecker, S., Puri, R., Hucko, T., Aradi, D., Herrman, J.-P. R., Hermanides, R. S., Wang, B., Wang, H., Butters, J., Di Giovanni, G., Jones, S., Pompili, G., & Psaltis, P. J. (2022). Effect of Evolocumab on Coronary Plaque Phenotype and Burden in Statin-Treated Patients Following Myocardial Infarction. JACC: Cardiovascular Imaging. https://doi.org/10.1016/j.jcmg.2022.03.002

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.